Thyroid Cancer News

Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid Cancer (June 6, 2017)

Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer. Up to 44 percent of papillary thyroid cancer... Continue Reading

Thyroid Cancer Survivors May Have Increased Risk of Osteoporosis and Heart Conditions (March 3, 2017)

The results of a recent new study find that younger survivors of thyroid cancer are at increased risk for osteoporosis, high blood pressure and heart disease.  Thyroid cancer is the fifth most common cancer in women. The thyroid gland is a butterfly-shaped... Continue Reading

More Risk than Benefit with TSH Suppression in Thyroid Cancer without High Risk of Recurrence (May 21, 2015)

For patients undergoing treatment for thyroid cancer who aren’t at high risk of recurrence, therapy to suppress thyrotropin (TSH) may be ineffective as well as risky. These findings were published in the journal Thyroid. Differentiated thyroid cancer... Continue Reading

Target Therapy Sutent® Promising in Advanced Thyroid Cancer (May 19, 2015)

The targeted therapy Sutent® (sunitinib) appears effective in the treatment of patients with advanced differentiated thyroid cancers. The Endocrine Society announced these Phase II trial findings in a press release. Study results were also presented... Continue Reading

Important Clues in the Development of Aggressive Thyroid Cancer (April 16, 2015)

New insight into how anaplastic thyroid cancer (ATC) grows and spreads may provide important direction in the development of treatment. These findings were published in the Journal of Clinical Endocrinology and Metabolism. The thyroid is a gland in the... Continue Reading

Nexavar Approved for Metastatic Differentiated Thyroid Cancer (December 9, 2013)

The U.S. Food and Drug Administration (FDA) has approved Nexavar® (sorafenib) for the treatment of metastatic differentiated thyroid cancer. Differentiated thyroid cancer is the most common type of thyroid cancer and can often be cured with surgery and... Continue Reading

Mutations Linked to Drug Response in Medullary Thyroid Cancer (November 15, 2013)

Metastatic medullary thyroid cancers with certain genetic mutations respond better to treatment with Cometriq™ (cabozantinib) than tumors without those mutations, according to the results of a study presented at the 83rd Annual Meeting of the American... Continue Reading

TSH Suppression after Thyroidectomy May Not Be Beneficial (November 4, 2013)

Suppression of thyroid-stimulating hormone (TSH) after thyroidectomy for low-risk cancer does not appear to reduce the risk of cancer recurrence and may even increase the risk of osteoporosis in women, according to the results of a study presented at... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Thyroid Ultrasound May Cut Biopsy Rate (September 13, 2013)

Thyroid ultrasound may help identify certain characteristics of thyroid nodules that can predict the likelihood of cancer—and subsequently help determine whether biopsy is necessary, according to the results of a study published in the Journal of the... Continue Reading

Latest Thyroid Cancer News By Stage

General Thyroid Cancer

Nexavar Approved for Metastatic Differentiated Thyroid Cancer (December 9, 2013)

The U.S. Food and Drug Administration (FDA) has approved Nexavar® (sorafenib) for the treatment of metastatic differentiated thyroid cancer. Differentiated thyroid cancer is the most common type of thyroid cancer and can often be cured with surgery and... Continue Reading

Mutations Linked to Drug Response in Medullary Thyroid Cancer (November 15, 2013)

Metastatic medullary thyroid cancers with certain genetic mutations respond better to treatment with Cometriq™ (cabozantinib) than tumors without those mutations, according to the results of a study presented at the 83rd Annual Meeting of the American... Continue Reading

TSH Suppression after Thyroidectomy May Not Be Beneficial (November 4, 2013)

Suppression of thyroid-stimulating hormone (TSH) after thyroidectomy for low-risk cancer does not appear to reduce the risk of cancer recurrence and may even increase the risk of osteoporosis in women, according to the results of a study presented at... Continue Reading

Thyroid Ultrasound May Cut Biopsy Rate (September 13, 2013)

Thyroid ultrasound may help identify certain characteristics of thyroid nodules that can predict the likelihood of cancer—and subsequently help determine whether biopsy is necessary, according to the results of a study published in the Journal of the... Continue Reading

BRAF V600E mutation Increases Death Risk in Papillary Thyroid Cancer (June 5, 2013)

The presence of the BRAF V600E mutation is significantly associated with increased cancer-related death among patients with papillary thyroid cancer, according to the results of a study published in the Journal of the American Medical Association. The... Continue Reading

More General Thyroid Cancer